logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Arcturus Therapeutics Additional Updates from ARCT-154 and ARCT-165 Clinical Trials and More

Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings ( ARCT ) is a clinical-stage mRNA medicines company of enabling technologies with an interesting pipeline of treatments and vaccines as well as other products for diseases that have yet to find treatments. Arcturus Therapeutics’...

Read More

December 16, 2021

0

Reata Pharmaceuticals Announces Extension of Review Period for Omaveloxolone NDA for Friedreich’s Ataxia

Reata Pharmaceuticals in the NEWS Reata Pharmaceuticals ( RETA ) on August 8, 2022, after the U.S. financial markets closed, received a communication from the U.S. Food and Drug Administration ( FDA ) informing us that they have extended the...

Read More

August 9, 2022

0

Gilead Sciences and Arcus Biosciences: Complete Closing of Option Exercises of 3 Programs. See Also: HOLD Put on Lenacapavir Due to Vial Quality Concern

Gilead Sciences and Arcus Biosciences Gilead Sciences ( GILD ) and Arcus Biosciences ( RCUS ) announced the closing of Gilead’s option exercises to three programs in Arcus’s clinical-stage portfolio and a new research collaboration between the two companies. On...

Read More

December 22, 2021

0

Compugen: More Highlighted News

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen ( CGEN ) and AstraZeneca ( AZN ) entered into an agreement by which Compugen provided an exclusive license to AstraZeneca for the development of bispecific and multi-specific antibody products...

Read More

December 23, 2020

0

Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences Good News for Breast Cancer Gilead Sciences' ( GILD )  product Trodelvy® has significantly improved the Overall Survival ( OS ) in Pre-Treated HR+/HER2- metastatic breast cancer patients in the TROPiCS-02 study. Today, Gilead Sciences' ( GILD )...

Read More

August 15, 2022

0

Inovio: Exciting News Published in The Lancet

Inovio Phase 1 Data of INO-4800 for COVID-19 Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA Vaccine Candidate, INO-4800, to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses. INO-4800 demonstrates favorable safety and tolerability. No...

Read More

December 24, 2020

0

Important and Encouraging News from Sutro Biopharma Inc

Sutro Biopharma Inc and Tasly Biopharmaceuticals Exclusive Licensing Agreement for STRO-002 In a press release from today, December 27, 2021, we learned that Sutro Biopharma Inc ( STRO ) and   Tasly Biopharmaceuticals Co., Ltd. - a holding subsidiary of...

Read More

December 27, 2021

0

For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

Intellia Therapeutics and CRISPR/Cas9 Technology Intellia Therapeutics ( NTLA ) is a genome editing company, focused on the development of potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both...

Read More

January 7, 2021

0

Underlining Exelixis Bright Future

Exelixis Bright Future Exelixis Fourth Quarter and Full Year 2020 Financial Results   Exelixis ( EXEL ) announced its preliminary unaudited financial results for the Fourth Quarter and Full Year 2020. It also provided financial guidance for the full year...

Read More

January 11, 2021

0

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA in Europe

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA La Jolla Pharmaceutical Company ( LJPC ) announced today in a press release that it and certain of its wholly-owned subsidiaries, La Jolla collectively, have entered into...

Read More

January 12, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 129
  • 130
  • 131
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy